National Institute of Allergy and Infectious Diseases (NIAID): Vaccinia trials

The registry lists 21 Vaccinia studies with National Institute of Allergy and Infectious Diseases (NIAID) as lead sponsor. 0 are open to participants now and 1 have results posted.

Phase 1 17Phase 2 3No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• High Dose IMVAMUNE® in Vaccinia-Naive IndividualsCompletedNCT00879762Phase 2Results posted
• VRC 208: Dose, Safety and Immunogenicity of a Recombinant Modified Vaccinia Virus Ankara Ebola Vaccine, VRC-EBOMVA079-00-VP (MVA-EbolaZ), Administered Alone or as a Boost to cAd3-Ebola Vaccines in Healthy AdultsCompletedNCT02408913Phase 1
• Evaluating the Safety and Immune Response of a Prime-Boost HIV Vaccine Regimen in Healthy, HIV-Uninfected, Vaccinia-Naive AdultsCompletedNCT01571960Phase 1
• Role of Antimicrobial Peptides in Host Defense Against Vaccinia VirusCompletedNCT00407069
• SIGA-246 to Treat SmallpoxWithdrawnNCT00303225Phase 1
• Phase I/II Trial of Modified Vaccinia Virus Ankara (MVA) Vaccine Against SmallpoxCompletedNCT00053742Phase 1
• APSV in Vaccinia Naive AdultsCompletedNCT00050518Phase 2
• Vaccinia Virus Vaccine (APSV) in Vaccinia- Naive Subjects: PILOTCompletedNCT00038987Phase 1/2
• Vaccinia Immune Globulin in Treating or Preventing Vaccinal InfectionWithdrawnNCT00006630Phase 1
• A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia Derived HIV-1 Recombinant Envelope Glycoprotein (gp160) of Human Immunodeficiency Virus: Evaluation of a 200-mcg DoseCompletedNCT00001056Phase 1
• A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination SchedulesCompletedNCT00001043Phase 1
• A Phase I, Multicenter, Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination SchedulesCompletedNCT00001037Phase 1
• A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope Vaccines in Vaccinia-Naive IndividualsCompletedNCT00001026Phase 1
• A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived HIV-1 Recombinant Envelope Glycoprotein (gp160)CompletedNCT00000968Phase 1
• A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia Derived HIV-1 Recombinant Envelope Glycoprotein (gp160) of Human Immunodeficiency Virus: Evaluation of Accelerated SchedulesCompletedNCT00000957Phase 1
• A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of the Therion Recombinant Vaccinia-HIV-1 IIIB ENV/GAG/POL Vaccine (TCB-3B) and MN RGP 120/HIV-1 In Alum.CompletedNCT00000866Not applicable
• A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV-1 IIIB Env/Gag/Pol Vaccine (TBC-3B)CompletedNCT00000767Phase 1
• A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of a Recombinant Vaccinia-HIV Envelope Vaccine (HIVAC-1e) in Combination With a Panel of Subunit Recombinant HIV Envelope VaccinesCompletedNCT00000746Phase 1
• A Phase I Multicenter, Randomized, Double-Blind Trial to Evaluate the Safety and Immunogenicity of Recombinant Vaccinia Virus Expressing the Envelope Glycoproteins of Human Immunodeficiency VirusCompletedNCT00000683Phase 1
• A Phase I Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-HIV Envelope Recombinant Vaccine (HIVAC-1e) in Combination With Soluble Recombinant Envelope Vaccine (VaxSyn)CompletedNCT00000631Phase 1
• Phase I Safety and Immunogenicity Trial of Vaccinia-HIV Envelope Recombinant Vaccine (HIVAC-1e) in Combination With Soluble Recombinant Envelope Vaccine (gp160; VaxSyn)CompletedNCT00000630Phase 1